Training the microbiota to increase immune checkpoint blockade and to reduce toxicity

Area of Science:

• Oncology
• Immunology
• Microbiome Research

Background:

• Immune checkpoint blockade (ICB) has revolutionized metastatic cancer treatment.
• Microbiota composition is increasingly recognized as a key factor influencing ICB response and toxicity.
• A significant proportion of patients do not respond to ICB or develop resistance.

Purpose of the Study:

• To summarize recent findings on modulating the gut microbiota to enhance ICB efficacy.
• To explore strategies for reducing ICB-related toxicity by targeting the microbiota.

Main Methods:

• Review of current scientific literature on microbiota manipulation and ICB.
• Analysis of data linking specific microbial compositions to treatment outcomes.
• Examination of prebiotics, probiotics, and postbiotics as microbiota-training agents.

Main Results:

• Specific bacterial species and genera are associated with ICB treatment response and adverse events.
• The dynamic nature of the microbiota offers opportunities for therapeutic intervention.
• Dietary interventions, prebiotics, probiotics, and postbiotics show promise in shaping the microbiota.

Conclusions:

• Modulating the gut microbiota is a promising strategy to improve cancer immunotherapy outcomes.
• Targeting the microbiota can potentially overcome resistance and mitigate toxicity associated with ICB.
• Further research into microbiota-based interventions is crucial for optimizing cancer treatment.